AML Subtype Is a Major Determinant of the Association between Prognostic Gene Expression Signatures and Their Clinical Significance

Caroline R M Wiggers, Mirna L Baak, Edwin Sonneveld, Edward E S Nieuwenhuis, Marije Bartels, Menno P Creyghton

Research output: Contribution to journal/periodicalArticleScientificpeer-review

Abstract

Relapse in acute myeloid leukemia (AML) may result from variable genetic origins or convergence on common biological processes. Exploiting the specificity and sensitivity of regulatory DNA, we analyze patient samples of multiple clinical outcomes covering various AML molecular subtypes. We uncover regulatory variation among patients translating into a transcriptional signature that predicts relapse risk. In addition, we find clusters of coexpressed genes within this signature selectively link to relapse risk in distinct patient subgroups defined by molecular subtype or AML maturation. Analyzing these gene clusters and the AML subtypes separately enhances their prognostic value substantially and provides insight in the mechanisms underlying relapse risk across the distinct patient subgroups. We propose that prognostic gene expression signatures in AML are valid only within patient subgroups and do not transcend these subgroups.

Original languageEnglish
Pages (from-to)2866-2877.e5
JournalCell Reports
Volume28
Issue number11
DOIs
Publication statusPublished - 10 Sep 2019

Fingerprint Dive into the research topics of 'AML Subtype Is a Major Determinant of the Association between Prognostic Gene Expression Signatures and Their Clinical Significance'. Together they form a unique fingerprint.

  • Cite this